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A RAC-GEF network critical for early intestinal
tumourigenesis
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D. M. Gay 1, J. Johansson1, R. P. Fordham1, B. Miller1, W. Clark1, A. Hedley1, E. B. Unal4,5,6, C. Kiel4, E. McGhee1,
L. M. Machesky 1,3, C. Nixon 1, A. E. Johnsson 7, M. Bain8, D. Strathdee 1, S. R. van Hoof9,10,
J. P. Medema9,10, K. I. Anderson 11, S. M. Brachmann12, V. M. Stucke12, A. Malliri 13, M. Drysdale14,
M. Turner 7, L. Serrano 4, K. Myant 15✉, A. D. Campbell 1✉ & O. J. Sansom 1,3✉
RAC1 activity is critical for intestinal homeostasis, and is required for hyperproliferation
driven by loss of the tumour suppressor gene Apc in the murine intestine. To avoid the impact
of direct targeting upon homeostasis, we reasoned that indirect targeting of RAC1 via RAC-
GEFs might be effective. Transcriptional profiling of Apc deficient intestinal tissue identified
Vav3 and Tiam1 as key targets. Deletion of these indicated that while TIAM1 deficiency could
suppress Apc-driven hyperproliferation, it had no impact upon tumourigenesis, while VAV3
deficiency had no effect. Intriguingly, deletion of either gene resulted in upregulation of Vav2,
with subsequent targeting of all three (Vav2−/− Vav3−/− Tiam1−/−), profoundly suppressing
hyperproliferation, tumourigenesis and RAC1 activity, without impacting normal homeostasis.
Critically, the observed RAC-GEF dependency was negated by oncogenic KRAS mutation.
Together, these data demonstrate that while targeting RAC-GEF molecules may have ther-
apeutic impact at early stages, this benefit may be lost in late stage disease.
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RAC1 is a Rho GTPase that exists in two conformationalstates, an active GTP-bound protein and an inactive GDP-bound protein1. Active RAC1 is vital for a multitude of
physiological processes, including cytoskeletal re-organisation,
cell division and cell migration2. It is primarily known for its key
role in regulating actin microfilament networks, being a major
regulator of lamellipodia formation and cell migration3,4, but it is
equally important for cell proliferation5,6. For example, in non-
small cell lung carcinoma, proliferation is dependent upon the
transcriptional activation of NF-kB by RAC17, whilst in vitro
studies have shown that RAC1 is required for cell proliferation
and G2/M progression in a rat fibroblast cell line6.
The requirement of RAC1 for transformation was first descri-
bed in the 1990s8, where RAC1 was shown to be overexpressed
and its activity increased in many human cancers. In addition, a
common activating mutation of RAC1 has recently been dis-
covered in melanoma, and RAC1B, a constitutively active splice-
variant of RAC1, is observed in colon cancer9,10. Additionally, a
recent CRISPR screen carried out by the Sabatini lab has suggested
that RAC1 activation may have a critical role in RAS-driven
tumourigenesis11. We and others have previously shown, using
genetically engineered mouse models, that RAC1 is an important
downstream effector of APC loss where mutations in the Apc gene
lead to the initiation of colorectal cancer (CRC)12–14. APC is a
negative regulator of the WNT signalling pathway and an essential
component of the destruction complex that targets β-catenin for
degradation by the proteasome15,16. Loss of APC results in the
translocation and accumulation of β-catenin in the nucleus, acti-
vation of the WNT pathway and if targeted to the stem cell
compartment, rapid adenoma formation17,18. Acute loss of APC
in vivo throughout intestinal lineages again drives WNT activation
and a crypt progenitor-cell phenotype with increased proliferation
and perturbed differentiation leading to a stem cell expansion,
mislocalisation of Paneth cells and a reduction in goblet and
enteroendocrine lineages14,17. Following APC loss, the stem cell
markers Lgr5 and Olfm4 are upregulated and the number of stem
cells present in the intestinal crypt is increased14. Loss of RAC1 is
sufficient to suppress the hyperproliferation of stem cells and the
tumourigenesis caused by APC loss. Mechanistically, this is in part
due to a reduction in NF-κB signalling14.
RAC-GTPase switches between active and inactive states, and
this switching is catalysed by Guanine Nucleotide Exchange
Factors (GEFs) and GTPase Activating Proteins (GAPs), respec-
tively19. GEFs promote the exchange of GDP for GTP which
causes a conformational change that exposes the effector binding
region of the GTPase, thus enabling it to transmit signals
downstream20,21. Currently, ~80 mammalian Rho GTPase GEFs
have been described22, divided into two subfamilies; the Dbl-
Pleckstrin Homology domain containing GEFs and DOCK180-
related GEFs23. Importantly, GEFs are upregulated in numerous
human cancers, e.g. PREX1 in melanoma and VAV1 in pan-
creatic cancer24,25.
Given that RAC1 activity is vital to tumour development and
progression, there is much focus on RAC1 as a pharmacological
target. However, there are multiple difficulties with targeting
RAC1 directly, as inhibitors of GTPases are notoriously either
inefficient, lacking specificity, or too toxic26. Additionally, loss of
RAC1 in the mouse is embryonically lethal27, and as we have
demonstrated, targeted loss of RAC1 from the intestinal epithe-
lium is detrimental to the structure of the intestinal villi. For
this reason, a more specific path must be pursued to allow tar-
geting of the cancer-related roles of RAC1 without affecting its
physiological roles. One option would be to inhibit specific cancer-
associated RAC1-GEFS, an approach exemplified by inhibitors
such as NSC23766, a small-molecule inhibitor which blocks the
interaction of a subset of GEFs, including TIAM1, with RAC1.
Over recent years, there has been significant interest in the
development of a greater understanding of the contribution of the
complex network of GEF molecules to cancer development and
progression, particularly in the setting of colorectal disease. This
has resulted in a wealth of observations related to the contribu-
tion of RAC-GEFs such as ASEF1, ASEF2 or TIAM1, both to
early adenoma formation, and to pathways critical for control of
aggressive cancer cell phenotypes. Intriguing studies have also
highlighted GEF independent roles for some of these molecules in
colorectal cancer progression28–30. In order to better understand
the contribution of RAC1-GEFs to phenotypes associated with
APC deficiency in colorectal cancer in vivo, we have undertaken
comparative transcriptional profiling of APC deficient and con-
trol intestinal tissues. Having identified the RAC-GEFs TIAM1,
VAV2 and VAV3 as potential candidates, we have gone on to
examine their roles in mediating phenotypes associated with APC
depletion. Critically, each of these genes has previously been
associated with promotion of tumourigenesis. For example,
expression of Vav2 is upregulated in head and neck squamous cell
carcinoma31, VAV3 is upregulated in Glioblastoma32,33, and
TIAM1 activity is an important factor in DMBA/TPA driven
HRAS mutated papilloma34,35. In the context of this study, GEF
molecules also have an important function in intestinal
tumourigenesis. By way of example, Malliri and colleagues
demonstrated that TIAM1 was an important driver of intestinal
tumourigenesis in the Apcmin/+ mouse model, in which tumours
arise through sporadic loss of heterozygosity of the Apc gene.
Here, they demonstrated that TIAM1 loss resulted in a sup-
pression of intestinal tumour initiation, though observed that
those tumours that did arise were more invasive30,36. Moreover,
the GEF molecule ARHGEF4 (ASEF1) has been shown to bind to
APC in HCT116 and SW480 cell lines, through an interaction
which relieves autoinhibition of ARHGEF4 itself, and results in
increased activity of CDC4228,29, with a further in vivo study into
the role of ARHGEF4 and the related molecule ASEF2 in in the
Apcmin/+ model, indicating that loss of either resulted in a
reduction in both size and number of intestinal adenomas37.
We show that although Rac1 deletion throughout the intes-
tinal epithelium causes defects in intestinal homeostasis, loss of
VAV2, VAV3 and TIAM1 is sufficient to strongly suppress
cancer phenotypes and tumourigenesis induced by APC loss,
whilst leaving the normal intestinal epithelium unperturbed.
Additionally, we demonstrate that the role of these GEFs
is context specific, as their ability to suppress the APC phenotype
is not recapitulated in an in vivo model of hepatocellular
tumourigenesis.
Finally, although hyperactivation of the WNT pathway
through loss of APC is thought of as the archetypal initiating
event in colorectal cancer, and alone is sufficient to drive intest-
inal polyposis in both human and mouse38,39, further oncogenic
mutations are required for progression to colorectal cancer40. We
demonstrate that oncogenic mutation of KRAS, a feature of ~40%
of human colorectal cancers41, and key driver of resistance to
current clinical therapeutic approaches, while remaining sensitive
to RAC depletion, drives profound resistance to deletion of
VAV2, VAV3 and TIAM1 in the absence of compensatory RAC-
GEF expression in vivo.
As a whole, the work presented here clearly demonstrates that
targeting RAC-GEFs is a promising avenue for suppression of the
RAC1 pathway, and could be highly efficacious in targeting early
stage disease. Critically, our work also highlights significant plasticity
associated with regulation of RAC1 activity, including compensatory
expression of RAC-GEFs, and resistance to RAC-GEF targeting eli-
cited by compounding oncogenic mutation of KRAS. These obser-
vations further strongly suggest that targeting RAC1-GEF molecules
alone may not be sufficient for cancer therapy in late stage disease.
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Results and discussion
RAC1 loss perturbs villus homeostasis. We have previously
shown that Rac1 deletion suppresses the “crypt progenitor-like”
phenotype, in addition to the tumourigenesis resulting from
APC deficiency14. This study suggested that targeting of RAC1
in intestinal cancer could be beneficial. Given that therapeutic
targeting of RAC1 in CRC would require suppression of activity
over a prolonged period of time, we sought to address the
consequences of RAC1 loss throughout the intestine, mimick-
ing the action of an inhibitor. We therefore generated Vil-
CreERT2 Rac1fl/fl mice and treated them with 2 mg tamoxifen
for 2 days to delete Rac1 throughout the intestinal epithelium
and observed the impact over time42,43. At 5 days post induc-
tion, mice developed symptoms of intestinal ill-health (weight
loss and hunching), were euthanised and the intestines har-
vested. Histological analyses show that while crypt structure,
including epithelial proliferation, appeared relatively unper-
turbed, there was a marked change in villus architecture
(Fig. 1a), with villi dramatically shortened and exhibiting
marked disintegration (Fig. 1a, arrow in Fig. 1a indicates dis-
integration, Supplementary Fig. 1B, D, E with Supplementary
Fig. 1A indicating the regions of interest of the crypt-villus) and
apoptosis (Fig. 1a and Supplementary Fig. 1C, F). To investigate
this more closely, we performed scanning EM of the intestinal
epithelium and found an altered morphology of the villus, with
clear bleb-like structures (as indicated by arrow Fig. 1b). Given
the role of RAC1 in maintaining the actin cytoskeleton, we
reasoned that the collapse of the villus structure and premature
cell sloughing may be due to a perturbed actin network. To
examine this, we crossed the Vil-CreERT2 Rac1fl/fl mice to mice
carrying the LifeAct-GFP reporter42,43. Gross perturbations in
F-actin structures were observed in the villus but not in the
crypts of these mice, as shown by intravital fluorescence ima-
ging (Fig. 1c). Together our data show that a reduction in RAC1
in the intestinal epithelium results in detrimental effects on
epithelial integrity and normal barrier function.
To verify the efficiency of deletion of Rac1 from this mouse
model, and show specificity of the Vil-CreERT2 promoter, we
designed a Rac1 BaseScope probe which allowed detection of
exons 4 and 5 (the specific exons lost upon induction). When
APC is lost, Rac1 is expressed throughout the intestine in both the
epithelial and stromal compartments. However, following
Fig. 1 Loss of Rac1 perturbs villus homeostasis. a Images showing H&E, BrdU incorporation and Cleaved caspase-3 IHC in Vil-CreERT2 (wild-type), Vil-
CreERT2 Rac1fl/fl (Rac1fl/fl) mice day 3 post induction and Vil-CreERT2 Rac1fl/fl (Rac1fl/fl) mice 3 and 5 days post induction. Red arrow indicates disintegrating
villus. Scale bar represents 100 μm in each case (See amplified images in Supplementary Fig. 1d–f). b Scanning EM on Vil-CreERT2 (Wild-type) or Vil-
CreERT2 Rac1fl/fl (Rac1fl/fl) intestines 4 days post induction. Red arrows indicate rounded, blebbing cells. Scale bar represents 100 μm in the upper panels
and 50 μm in the lower panels. c Vil-CreERT2 driving expression of LifeAct-GFP in wild-type and Rac1fl/fl intestines 4 days post induction. Scale bar
represents 50 μm.
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targeted deletion of Rac1 alongside APC deletion using the Vil-
CreERT2 promoter, we observed a striking loss of Rac1 expression
specifically in the intestinal epithelium (Supplementary Fig. 2A).
This is further verified by reduction in RAC1 protein as shown by
immunohistochemical analysis using a RAC1 antibody (phospho
S71; Supplementary Fig. 2B). Interestingly, despite the similarities
in signalling pathways between RAC1 and CDC42 and being
close homologues4,5,44, CDC42 expression is unaffected by loss of
RAC1 (Supplementary Fig. 2C).
VAV3 and TIAM1 are upregulated following APC loss. In light
of the intestinal toxicity associated with RAC1 loss, we used RNA-
seq analysis to profile the GEFs expressed in the murine small
intestine, comparing wild-type tissue to APC-deficient tissue and
observed distinct differential expression as shown by a principle
component analysis (PCA; Supplementary Fig. 3A). This analysis
showed that Ect2, Tiam1, Arhgef4 and Vav3 were highly upre-
gulated following APC loss (Fig. 2a and Supplementary Fig. 3A).
Although Ect2 was the most induced GEF following APC loss and
has previously been associated with tumourigenesis in the brain32,
it is also known that constitutive knockout of Ect2 in the mouse is
embryonic lethal45. Ect2 has also been identified as a common
essential gene through CRISPR and RNAi screening (DEPMAP
project46) raising concerns related to toxicity that may be
encountered through therapeutic targeting of ECT2. Additionally,
ARHGEF4 has been identified as a CDC42 specific GEF28. As
such, our research initially focussed upon targeting of the induced
GEFs TIAM1 and VAV3 in intestinal tumourigenesis driven by
APC loss. Intriguingly, VAV1 is sparsely expressed and pre-
dominantly seen in stromal tissue, despite showing high sequence
similarity to VAV2 and VAV3 (Supplementary Fig. 3B–E).
Interestingly, in wild-type intestine, VAV2 is predominantly
expressed in the stromal compartment, while following loss of
APC, it becomes highly expressed in the intestinal epithelium
(Supplementary 4A, B). This indicates that while expression of
VAV2 may not appear to be induced in whole intestinal tissue, it
is induced in the intestinal epithelium following APC depletion
and as such is of significant interest. To investigate potential
compensation between VAV2 and VAV3, we examined Vav2
expression in Vil-CreERT2 Apcfl/fl Vav3–/– mice by RNAscope and
observed a significant increase in Vav2 expression compared to
Vil-CreERT2 Apcfl/fl mice (an average of 36.27 probes per crypt
were observed in Vil-CreERT2 Apcfl/fl compared to 69.64 probes
per crypt, a fold change of 1.92; Fig. 2b, c).
The observed induction of VAV2 and VAV3 in the murine
intestinal epithelium following Apc deletion is also reflected in
human disease. Recent efforts to classify the molecular subtypes
of human colorectal cancer (CRC) based upon large scale
genomic, transcriptional and proteomic data have identified four
major consensus molecular subtypes (CMS1-4)47. Of these, CMS2
is most closely associated with APC loss and altered regulation of
the canonical WNT pathway, and as such most closely related to
our in vivo model. Interrogation of the transcriptional profiles
of VAV2, VAV3 and TIAM1 in a patient-derived CRC dataset
indicated that expression of both VAV2 and VAV3 is particularly
enriched in the APC loss associated CMS2 subtype. TIAM1
expression is found in all CMS subtypes of CRC, however it is
markedly lower than that of VAV2 and VAV3 (Supplementary
Fig. 5).
Loss of one or two intestinal GEFs is insufficient to rescue the
phenotype caused by APC loss. Based on the GEF expression
levels and the observed compensation between VAV2 and VAV3,
we examined the impact of Tiam1 deletion and of combined
Vav2/Vav3 knockout on the phenotypes caused by intestinal
APC loss.
We generated Vil-CreERT2 Apcfl/fl Vav2−/− Vav3−/− (APC
V2V3) and Vil-CreERT2 Apcfl/fl Tiam1−/− (APC T) mice and
compared these to control Vil-CreERT2 Apcfl/fl (APC). We
induced APC loss in the intestine by Cre-induction with
tamoxifen, and analysed the mice 4 days later. At this time, the
APC-deficient intestines developed the expected “crypt progeni-
tor-like” phenotype, with mice developing large hyperprolifera-
tive crypts, alongside an increase in stem cell markers (visualised
here by RNAscope for Lgr5 and Olfm4; Fig. 3a)17. To validate
loss of the GEFs, immunohistochemical analysis was performed
(Supplementary Fig. 4B). Here we demonstrate a loss of VAV2
and VAV3 expression in APC V2V3 intestines. The expression of
VAV2 was unaffected by loss of TIAM1 (when compared to
APC). Additionally, using CTGF as a marker for TIAM1
activity48, we observed an increase in cytoplasmic CTGF upon
loss of TIAM1 in APC T, indicating a loss of TIAM1 activity.
Loss of VAV2 and VAV3 slightly exacerbated the crypt
progenitor phenotype driven by APC deficiency, resulting in a
slight but significant increase in crypt cell proliferation (Fig. 3a, b
and Supplementary Fig. 6A–C). In contrast, Tiam1 knockout
reduced hyperproliferation associated with APC loss, but did not
impact the increase in stem cell marker expression (Fig. 3a, b and
Supplementary Fig. 6A–C). To examine the stem cell phenotype
functionally, we used an in vitro clonogenicity assay where APC-
deficient intestinal single-cell suspensions are able to re-grow into
organoid spheres within 5 days. Consistent with the finding that
deficiency of both VAV2 and VAV3 or TIAM1 had no effect on
stem cell marker expression dependent upon APC loss, intestinal
cells from mice lacking both VAV2 and VAV3 or TIAM1
retained the ability to form organoids (Fig. 3c).
Finally, to investigate whether GEF deficiency had a functional
effect on tumourigenesis, we generated Lgr5-EGFP-IRES-creERT2
Apcfl/fl (Lgr5 APC), Lgr5-EGFP-IRES-creERT2 Apcfl/fl Vav2−/−
Vav3−/− (Lgr5 APC V2V3) and Lgr5-EGFP-IRES-creERT2 Apcfl/fl
Tiam1−/−(Lrg5 APC T) mice, examining the role of these GEFs
when Apc is deleted solely from the intestinal stem cells.
Homozygous deletion of Apc was induced in these mice using a
4-day protocol of tamoxifen treatment14, with mice aged until
they developed signs of intestinal neoplasia (weight loss and
hunching). This is a rapid model of tumourigenesis, in contrast to
other models where initiation of tumourigenesis is dependent
upon the spontaneous loss of the second copy of Apc. The
majority of the Lgr5 APC mice reach endpoint and display
clinical signs by day 25 post induction (Fig. 3d, e)18. Neither
VAV2/VAV3-deficiency nor TIAM1-deficiency slowed tumour-
igenesis caused by APC loss (Fig. 3d, e). While these ageing
cohorts were carried out independently, each cohort had its own
control Lgr5 APC arm between which no survival difference was
observed (Supplementary Fig. 6D). Histologically, the adenomas
that formed in Lgr5 APC V2V3 mice or in Lgr5 APC T mice were
similar to those in mice lacking only APC in lesion burden, lesion
structure and cellular proliferation at endpoint (Fig. 3f, g and
Supplementary Fig. 6C).
Taken together, these data show that the single deletion of the
RAC-GEF Tiam1 or the double deletion of Vav2 and Vav3
was insufficient to recapitulate the phenotype caused by RAC1
deficiency (namely an extension in survival following APC loss)14.
Moreover, TIAM1 deficiency, which resulted in reduced prolifera-
tive capacity following acute deletion of APC (Fig. 3b), was unable to
extend survival in the Lgr5 APC ageing model of CRC, suggesting
that reduced proliferation alone is insufficient to impair efficient
tumourigenesis. It should be noted that our data differ somewhat
from the previous study in the Apcmin/+ mouse, which showed that
TIAM1 loss slows tumourigenesis30. We believe this is due to
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Fig. 2 VAV3 and TIAM1 are upregulated following APC loss. a Heatmap derived from RNA-seq analysis comparing whole tissue from wild-type (Vil-
CreERT2) and APC intestines (Vil-CreERT2 Apcfl/fl) n= 3 biologically independent animals for both APC and WT intestinal tissue. Log2FC of GEF expression
displayed on the right, genes significantly deregulated displayed in bold (FDR < 0.05) displayed in bold. b RNAscope of Vav2 in the intestinal epithelium of
Vil-CreERT2 Apcfl/fl (APC) and Vil-CreERT2 Apcfl/fl, Vav3−/− (APC V3) mice, Scale bar represents 100 μm. c Quantification of Vav2 RNAscope from Vil-
CreERT2 Apcfl/fl and Vil-CreERT2 Apcfl/fl Vav3−/− intestines. N= 5 biologically independent animals for each genotype. P= 0.0079 as determined by a two-
tailed Mann–Whitney test. Data are presented as mean values ±SD.
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differences between the two models. The Apcmin/+ model of
tumourigenesis is dependent on a spontaneous loss of the second
copy of Apc, whereas the Lgr5-EGFP-IRES-creERT2 Apcfl/fl (Lgr5
APC) model has both copies of Apc lost at induction which results
in rapid tumourigenesis elicited in the LGR5 positive stem cell
compartment. It is possible that the effect of TIAM1 on the
hyperproliferative phenotype suppresses growth early on, with some
APC-deficient clones potentially arising outside of the stem
cell zone.
Loss of VAV2, VAV3 and TIAM1 are required to suppress the
cancer phenotype caused by APC loss. Given the increased Vav2
expression in Vil-CreERT2 Apcfl/fl Vav3–/– mice, we also assayed
Vav2 expression in Vil-CreERT2 Apcfl/fl Tiam1−/− intestines and
observed a significant increase by RNAscope analysis (an average
of 36.27 probes per crypt were observed in Vil-CreERT2 Apcfl/fl
mice compared to 59.45 probes per crypt in Vil-CreERT2 Apcfl/fl
Tiam1−/− mice, a fold change of 1.64; Fig. 4a, b). Additionally, we
performed IHC analysis of VAV2 on these samples and observed
strong epithelial staining in Vil-CreERT2 Apcfl/fl, Tiam−/− mice
(Supplementary Fig. 4B). Given the upregulation of transcription
of Vav2 and the high expression following loss of TIAM1
alongside APC, we therefore reasoned that VAV2 might also
compensate for TIAM1 and thus generated Vav2−/− Vav3−/−
Tiam1−/− triple-GEF whole body knockout mice (V2V3T).
These mice are viable and exhibit normal intestinal homeostasis
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(Fig. 4c). We intercrossed triple-GEF knock-out mice with Vil-
CreERT2 Apcfl/fl mice to generate Vil-CreERT2 Apcfl/fl Vav2−/−
Vav3−/− Tiam1−/− (APC V2V3T), in which APC loss could be
induced by tamoxifen. Loss of VAV2, VAV3 and TIAM1
expression in this system was demonstrated by immunohisto-
chemical staining (Supplementary Fig. 4B). This model was then
used to investigate whether triple-GEF deficiency was sufficient to
modify the crypt progenitor-like phenotype caused by APC loss.
Four days after induction of APC loss, triple-GEF deficiency
resulted in a significant decrease in intestinal cell proliferation (as
shown by BrdU incorporation) compared to controls, to a similar
level caused by TIAM1 deficiency alone (Figs. 3b and 4c, d). In
contrast, the triple-GEF deficient mice (V2V3T) also showed a
marked reduction in the expression of the stem cell marker Lgr5,
whilst Olfm4 remained largely unchanged (Fig. 4c and Supple-
mentary Fig. 7). We validated this observation through the clo-
nogenicity assay, where cells lacking the three GEFs, as well as
APC loss (APC V2V3T), exhibited reduced spheroid-forming
capacity compared to APC loss alone or to our previous experi-
ments where 1 or 2 GEFs were lacking (Fig. 4e). Given that we
observed not only a reduction in cell proliferation but also a
triple-GEF dependent reduction in stem cell marker expression,
we assessed whether deletion of these three GEFs was also suf-
ficient to modify tumourigenesis caused by APC loss.
We generated Lgr5-EGFP-IRES-creERT2 Apcfl/fl Vav2−/− Vav3−/−
Tiam1−/− (Lgr5 APC V2V3T) mice to directly compare with Lgr5-
EGFP-IRES-creERT2 Apcfl/fl mice (Lgr5 APC) to determine the effect
of triple-GEF deficiency on tumourigenesis. Apc deletion was induced
as described above, and was performed within the same breeding
colony as the Lgr5 APC V2V3 cohort; as such the Lgr5 APC survival
data are the same for both ageing studies. Importantly, mice lacking
all 3 GEFS (Lgr5 APC V2V3T) showed a marked delay in
tumourigenesis when compared to control Lgr5 APC mice (p=
0.0091 as determined by Mantel–Cox log rank, Median times to
intestinal tumourigenesis 43 days vs 23 days; Fig. 4f). As previously,
tumour burden at endpoint was consistent between these two cohorts
(Fig. 4g). In addition to enhanced survival, histological differences
were observed; while adenomas which developed in control animals
were solid (indicated by asterisk in Fig. 4h), those that developed in
Lgr5 APC V2V3T mice were more cystic (Indicated by arrow in
Fig. 4h). This was reminiscent of the adenomas observed in Lgr5-
EGFP-IRES-creERT2 Apcfl/fl Rac1fl/fl mice (Fig. 4h)14, suggesting that
loss of VAV2, VAV3 and TIAM1 could phenocopy the effect of
RAC1 loss. To confirm the ability of these three GEFS to suppress
colorectal carcinogenesis, we performed an Azoxymethane/Dextran
Sodium Sulfate (AOM/DSS) colitis-associated cancer protocol and
found that the triple-GEF knockout mice (V2V3T) developed far
fewer tumours (Fig. 4i).
Taken together, our data show that these three GEFs, VAV2,
VAV3 and TIAM1 are required for the crypt progenitor
phenotype and tumourigenesis caused by APC loss in the
intestinal stem cell compartment. Deficiency in these three
GEFs thus faithfully recapitulates the Rac1-deletion phenotype.
It is interesting to note that tumourigenesis was only affected
when the stem cell marker levels were reduced and clonogeni-
city in culture impaired, reinforcing the importance of stemness
for tumourigenesis. It should also be noted that in the presence
of functional APC, triple-GEF knockout intestines had similar
levels of intestinal stem cell markers compared to wild-type
mice; thus the reduced tumourigenesis was not simply a
reflection of fewer intestinal stem cells (Fig. 4c and Supple-
mentary Fig. 7C).
Given that the stem cell targets are known to be driven by
WNT signalling, we next examined expression of a broader set of
WNT targets and nuclear localisation of β-catenin in the triple-
GEF mice following APC loss. In APC-deficient mice, we saw a
marked induction in the levels of nuclear β-catenin and induction
of targets such as CD44, SOX9, c-Myc and Axin2. Consistent with
our previous studies where we deleted Rac1, loss of the three
GEFS did not reduce the accumulation of β-catenin in the
nucleus14 or the expression of CD44, SOX9 or c-Myc. In contrast,
there was a marked downregulation in the levels of Axin2, a well-
established component of the destruction complex49, again
supporting the critical role of RAC1 activity downstream of
APC loss (Supplementary Figs. 8 and 9). These data specifically
address the potential of a therapeutic window for targeting RAC1.
Whilst we have previously shown that loss of RAC1 has a
catastrophic effect on the gut (Fig. 1a), targeting of specific RAC-
GEFs is capable of suppressing proliferation whilst not impacting
the structural integrity of the intestine.
These collective observations are consistent with previous work
which has shown that whilst RAC1 is not required for the nuclear
accumulation of β-catenin, it is required to mediate phosphoryla-
tion of β-catenin at residues S191 and S605 by JNK2, resulting in
enhanced activation of WNT-dependent genes50. In the absence of
these WNT targets, the transforming programme of APC loss,
which drives the crypt progenitor phenotype cannot be fully
established, with key functional targets such as Axin2 being
reduced. This provides a ready explanation for the delay in
tumourigenesis in these triple-GEF knockout mice.
Fig. 3 Loss of a single or double GEF is unable to rescue the Apcfl/fl phenotype. a H&E, BrdU incorporation and RNAscope for Lgr5 and Olfm4 on Vil-
CreERT2 Apcfl/fl (APC), Vil-CreERT2 Apcfl/fl, Vav2−/−, Vav3−/− (APC V2V3) and Vil-CreERT2 Apcfl/fl Tiam1−/− (APC T). Scale bar represents 100 μm for
H&E and BrdU and 50 μm for RNAscope images. b Quantification of BrdU positive cells. N= 6, 5 and 6 biologically independent animals for Vil-CreERT2
Apcfl/fl (APC), Vil-CreERT2 Apcfl/fl, Vav2−/−, Vav3−/− (APC V2V3; p= 0. 0303 as determined by a two-tailed Mann–Whitney) and Vil-CreERT2 Apcfl/fl
Tiam1−/− (APC T; *p= 0.0260, as determined by a two-tailed Mann–Whitney) respectively. Data are presented as mean values ±SD. c Quantification of
clonogenicity assay of intestinal organoids. N= 6, 3 and 3 biologically independent animals for Vil-CreERT2 Apcfl/fl (APC), Vil-CreERT2 Apcfl/fl, Vav2−/−,
Vav3−/− (APC V2V3; p= 0.5476, as determined by a two-tailed Mann–Whitney) and Vil-CreERT2 Apcfl/fl Tiam1−/− (APC T) respectively (p= 0.5476, as
determined by a two-tailed Mann–Whitney). Data are presented as mean values ±SD. d, e Survival of Lgr5-EGFP-IRES-creERT2 Apcfl/fl (Lgr5 APC), Lgr5-
EGFP-IRES-creERT2 Apcfl/fl Vav2−/−, Vav3−/− (Lgr5 APC V2V3) and Lgr5-EGFP-IRES-creERT2 Apcfl/fl Tiam1−/− (Lgr5 APC T). d N= 19 and 18 biologically
independent animals for Lgr5 APC and Lgr5 APC V2V3 respectively (p= 0.7142, as determined by Log-rank (Mantel-Cox) test). e N= 15 and 10
biologically independent animals for Lgr5 APC and Lgr5 APC T respectively (under the control of Lgr5-EGFP-IRES-creERT2). (p= 0.1982, as determined by
Log-rank (Two-tailed Mantel-Cox test). The same Lgr5 APC control cohort was used in both d and e as well as in Fig. 4f and Supplementary Fig. 6D.
f Quantification of intestinal tumour burden following APC loss in the Lgr5 stem cell compartment. Tumour burden is determined as percentage of intestine
which is covered by lesion or adenomas. Lgr5-EGFP-IRES-creERT2 Apcfl/fl (APC; n= 9 biologically independent animals) vs Lgr5-EGFP-IRES-creERT2 Apcfl/fl
Vav2−/−, Vav3−/− (APC V2V3; n= 6 biologically independent animals) p= >0.9999 as determined by a two-tailed Kruskal–Wallis with Dunn’s multiple
comparisons test. Lgr5-EGFP-IRES-creERT2 Apcfl/fl (APC) vs Lgr5-EGFP-IRES-creERT2 Apcfl/fl Tiam1−/− (APC T; n= 7 biologically independent animals), p=
0.7532 as determined by a two-tailed Kruskal–Wallis with Dunn’s multiple comparisons test. Data are presented as mean values ±SD. g Solid adenomas
(H&E) were observed in each genotype, indicated by the arrow. Scale bar represents 500 μm.
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The role of VAV2, VAV3 and TIAM1 on WNT-driven pro-
cesses is intestine-specific. One important question that
remained was how specific this transcriptional network of GEF
expression resulting from WNT activation was to intestinal dis-
ease. As mentioned previously, triple knockouts are viable and
fertile with normal intestinal homeostasis, suggesting little impact
on WNT signalling under homeostatic conditions. For this rea-
son, we examined potential induction and functional relevance of
these RAC-GEFS in models of hepatocellular disease, a second,
independent in vivo model of WNT-driven hyperproliferation. It
has previously been shown that loss of APC in the adult murine
liver results in an increase in nuclear β-catenin accumulation and
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c-Myc expression, which is associated with hyperproliferation and
hepatomegaly51,52. We induced loss of APC in the liver using
AAV-TBG-Cre53. Consistent with previous studies, we observed
nuclear accumulation of β-catenin and an increase in liver size in
this setting (Supplementary Fig. 10A, B). Interestingly, when we
carried out the deletion of Apc alongside deletion of Rac1 using
AAV-TBG-Cre, or in the context of mice lacking VAV2, VAV3
and TIAM1, we did not observe rescue of WNT-driven pheno-
types; more specifically we saw no impact upon liver weight or
liver enzyme production (Supplementary Fig. 10B–E). While this
experiment is not able to demonstrate a critical role for VAV2,
VAV3 or TIAM1 for RAC1 activation in hepatocellular pro-
liferation, it does critically demonstrate that the requirement for
RAC1 activity in WNT-driven hyperproliferation is not uniform.
This further indicates that targeting of RAC1 regulatory mole-
cules for anti-cancer impact may prove to be highly context
dependent.
Intestinal RAC activity is reduced in triple-GEF knockout
mice. In order to examine the effect of VAV2, VAV3 and TIAM1
deficiency on RAC1 activity in the intestine, we initially looked at
the levels of total RAC1. Immunohistochemical analysis showed
loss of the GEFs alongside APC resulted in no discernible dif-
ference in the amount of total RAC1 present when compared to
Vil-CreERT2 Apcfl/fl mice alone (Supplementary Fig. 11).
To better understand gross RAC1 activity in APC-deficient
intestinal tissue when compared to APC V2V3T intestinal tissues,
we performed immunoprecipitation assays with a RAC1-GTP
specific antibody. This approach demonstrated that the overall
proportion of GTP bound or “active” RAC1 in APC-deficient
intestinal tissue is substantially lower in the absence of VAV2,
VAV3 and TIAM1 (Fig. 5a). To complement this gross or bulk
approach to assessment of RAC1 activity, we took advantage of
the previously described genetically engineered mouse expressing
a Raichu-RAC1 FRET probe54,55. This probe was previously
shown to enable the quantification of active RAC1 in live tissues
and cells, whilst leaving the cell properties and responses
unaffected. Johnsson et al. previously detected Raichu-RAC1
expression in organoid intestinal cultures and showed spatial and
temporal regulation of RAC1 activity in these cultures particularly
Fig. 4 Loss of three GEFs is able to suppress the loss of Apc phenotype. a RNAscope staining for Vav2 in intestine from Vil-CreERT2 Apcfl/fl (APC) and Vil-
CreERT2 Apcfl/fl Tiam1−/− (APC T) intestines. Scale bar represents 100 μm. b Quantification of Vav2 RNAscope in Vil-CreERT2 Apcfl/fl (APC) and Vil-CreERT2
Apcfl/fl Tiam1−/− (APC T) intestines. N= 5 biologically independent animals for each genotype *p= 0.0159 as determined by a two-tailed Mann–Whitney
test. Data are presented as mean values ±SD. c Images for H&E and BrdU incorporation and RNAscope for Lgr5 and Olfm4 on wild-type (WT), Vav2−/−,
Vav3−/ Tiam1−/− (V2V3T), Vil-CreERT2 Apcfl/fl (APC) and Vil-CreERT2 Apcfl/fl, Vav2−/− and Vav3−/−Tiam1−/− (APC V2V3T). Scale bar represents 100 μm
for H&E and BrdU and 50 μm for RNAscope images. d Quantification of BrdU positive cells. N= 7, 6 and 8 biologically independent animals for wild-type, Vil-
CreERT2 Apcfl/fl (APC) and Vil-CreERT2 Apcfl/fl, Vav2−/− and Vav3−/− Tiam1−/− (APC V2V3T) respectively. WT vs APC ***p= 0.0006, APC vs APC V2V3T
*p= 0.0013 as determined by a one-tailed Mann–Whitney test. Control data (APC) as in Fig. 3c. Data are presented as mean values ±SD.
e Quantification of clonogenicity assay of intestinal organoids. N= 6 biologically independent cell lines for both Vil-CreERT2 Apcfl/fl (APC) and Vil-CreERT2
Apcfl/fl, Vav2−/−, Vav3−/− Tiam1−/− (APC V2V3T). *p= 0.0260 as determined by a two-tailed Mann–Whitney test. f Compared to Lgr5-EGFP-IRES-creERT2
Apcfl/fl (Lgr5 APC), Lgr5-EGFP-IRES-creERT2 Apcfl/fl Vav2−/−, Vav3−/− Tiam1−/− (Lgr5 APC V2V3T) mice have a significant survival advantage. N= 19 and
15 biologically independent animals for Lgr5 APC and Lgr5 APC V2V3T respectively. **p= 0.0091 as determined by a two-tailed Log-rank (Mantel-Cox)
test. Lgr5 APC control cohort is the same cohort as used in Fig. 3d, e as well as Supplementary Fig. 6D. Data are presented as mean values ±SD.
g Quantification of intestinal tumour burden at clinical endpoint following APC loss in the Lgr5 stem cell compartment. N= 8 and 9 biologically independent
animals for Lgr5-EGFP-IRES-creERT2 Apcfl/fl (Lgr5 APC) and Lgr5-EGFP-IRES-creERT2 Apcfl/fl Vav2−/−, Vav3−/− Tiam1−/− (Lgr5 APC V2V3T) respectively. p=
0.9522 as determined by a two-tailed Mann–Whitney test. Data are presented as mean values ±SD. h Solid adenomas (asterisk) were observed in the Lgr5-
EGFP-IRES-creERT2 Apcfl/fl (Lgr5 APC) cohort, whereas cystic adenomas were observed (H&E) in Lgr5-EGFP-IRES-creERT2 Apcfl/fl Vav2−/−, Vav3−/− Tiam1−/−
(Lgr5 APC V2V3T) and Lgr5-EGFP-IRES-creERT2 Apcfl/fl, Rac1fl/fl (Lgr5 APC Rac1), as indicated by arrows. Scale bar represents 100 μm. i Intestinal tumour
number in an AOM-DSS colitis-associated model of tumourigenesis. Study was carried out on wild-type mice or Vav2−/−, Vav3−/− Tiam1−/− mice. N= 9
and 4 biologically independent animals for wild-type or Vav2−/−, Vav3−/− Tiam1−/− respectively. **p= 0.0042 as determined by a one-tailed
Mann–Whitney Test. Data are presented as mean values ±SD.
Fig. 5 Loss of the triple GEFs results in a downregulation of junctional
RAC1 activity. a Immunoprecipitation of Active RAC1 from intestinal
epithelium, blotted with total RAC1 and the corresponding scoring. n= 3
biologically independent samples for Vil-CreERT2 Apcfl/fl (APC) and Vil-
CreERT2 Apcfl/fl, Vav2−/−, Vav3−/− Tiam1−/− (APC V2V3T). *p= 0.00799
as determined by a one-tailed Mann–Whitney test. Data are presented as
mean values ±SD. b FLIM-FRET analysis of organoids day 3 post isolation
from Vil-CreERT2 Apcfl/fl (APC) and Vil-CreERT2 Apcfl/fl Vav2−/−, Vav3−/−,
Tiam1−/− (APC V2V3T) Scale bar represents 20 μm. c Quantification of
FLIM-FRET analysis at cell–cell contacts. N= 3 biologically independent cell
lines derived from independent mice for each genotype. *p= 0.0426 as
determined a two-tailed unpaired T-test. Data are presented as mean
values ±SD.
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in the stem-cell niche. Given the versatility of this Raichu-RAC1
probe, we crossed the Raichu-Rac1-FRET mice to Vil-CreERT2
Apcfl/fl Vav2−/− Vav3−/− Tiam1−/− mice in order to quantify
RAC1 activity caused by APC loss, which is dependent on the
triple-GEF expression. In these organoid cultures, we were able to
utilise FLIM-FRET imaging to quantify RAC1 activity. This
approach indicated a decrease in RAC1 activity in APC V2V3T
organoids when compared to APC controls, as demonstrated by
an increase in fluorescence lifetime (Fig. 5b, c). We have
previously demonstrated that following APC loss in the intestinal
epithelium, RAC1 has a role in generation of reactive oxygen
species (ROS)14. Critically this is a RAC1 specific function, as
CDC42 is unable to stimulate ROS generation through
NADPH56. In the present study, reduced lipid peroxidation
indicated by immunohistochemical staining of malondialdehyde
(MDA) in the intestinal epithelium of APC V2V3T or APC
Rac1fl/fl when compared to APC controls suggests a suppression
of ROS generation in the context of reduced RAC1 activity
(Supplementary Fig. 11A, B).
Oncogenic mutation of KRAS drives resistance to RAC-GEF
depletion. In this simple model of adenoma formation in the
intestinal epithelium, we have observed marked compensation
between GEFs at the level of transcription. Critically, both the
data described above, and the regulatory complexity generated
both transcriptionally and functionally by the expression of 60+
multidomain cellular RAC-GEFs, implies significant plasticity in
regulation of GTPase signalling in response to altered cellular or
environmental cues. For this reason, we sought to determine
whether a further compounding oncogenic KRAS mutation could
impact sensitivity to RAC-GEF depletion in vivo. Clinically,
KRAS mutant colorectal cancers are refractory to current treat-
ments, and critically, one could envisage that significant alteration
to signalling flux through oncogenic pathways controlled by
KRAS could have a significant impact upon RAC-GEF and
consequently RAC GTPase activity. To investigate this, we
intercrossed an oncogenic LSL-KRasG12D allele57 to the
Vil-CreERT2 Apcfl/fl Rac1fl/fl and Vil-CreERT2 Apcfl/fl Vav2−/−
Vav3−/− Tiam1−/− models described both above and pre-
viously14. This approach allowed us to test the impact of a strong
oncogenic drive upon sensitivity to genetic targeting of either
Rac1 alone or a combination of the RAC-GEFs Vav2, Vav3,
Tiam1. As previously reported, targeting of oncogenic KRAS to
the intestinal epithelium in the context of APC depletion results
in exacerbated crypt expansion driven by a significant increase in
cellular proliferation58. Here, enhanced KRAS driven crypt
expansion retained sensitivity to homozygous depletion of RAC1,
indicating that in the context of KRAS mutation, RAC1 signalling
remains a fundamental determinant of cellular proliferation.
Notably, despite the retained sensitivity to RAC1 depletion, the
presence of an oncogenic KRAS mutation drove resistance to the
combined depletion of VAV2, VAV3 and TIAM1, with no sig-
nificant reduction in epithelial cell proliferation observed in Vil-
CreERT2 Apcfl/fl KrasG12D/+ Vav2−/− Vav3−/− Tiam1−/− when
compared to Vil-CreERT2 Apcfl/fl KrasG12D/+ control (Fig. 6a, b).
Indeed, in contrast to APC deficiency, depletion of VAV2, VAV3
and TIAM1 had no impact upon intestinal stem marker or WNT
target gene expression in KRAS mutant tissue (Fig. 6c–g). Con-
sistent with these observations, RAC1 depletion was sufficient to
suppress intestinal stem cell marker expression, suggesting that
RAC1 activity may be uncoupled from VAV2, VAV3 and TIAM1
activity in the context of KRAS mutation (Fig. 6c–g). In light of
these observations, along with the altered transcriptional regula-
tion of RAC-GEFs driven by APC depletion, and the impact that
oncogenic KRAS mutation has upon GTPase signalling at the
network level59, it is conceivable that KRAS mutation may result
in transcriptional control of alternative RAC-GEF molecules. We
sought to address this question through comparative transcrip-
tional profiling of RAC-GEF expression in intestinal tissue from
Vil-CreERT2 Apcfl/fl and Vil-CreERT2 Apcfl/fl KrasG12D/+ mice.
Intriguingly, we found that expression of oncogenic KRAS
mutation did not broadly impact the transcription RAC-GEFs
(Supplementary Fig. 12). Thus, the lack of phenotypic effect of
RAC-GEF deletion following KRAS mutation may be due to a
functional rewiring of cellular signalling upstream of RAC1,
either through transcriptional adaptation, or via modified sig-
nalling flux through individual molecules or networks of RAC-
GEFs. While intriguingly, the lack of a broader KRAS driven
function in APC-deficient tissue may be to support activity of
KRAS dependent signalling processes, a role rendered redundant
by oncogenic KRAS mutation. Certainly, these observations
suggest a deeper understanding of the impact of KRAS mutation
upon RAC1 activity in CRC appears of critical importance.
The observations detailed here serve to underline the
importance of RAC1 GTPase signalling in the regulation of
growth and survival of transformed cells in vivo. Moreover, the
data suggest that the targeting of specific RAC-GEFs should be
informed not only by basal expression or transcriptional
induction, but also with consideration of basal activity. Whilst
we have demonstrated that combined targeting of VAV2, VAV3
and TIAM1 has significant impact upon phenotypes associated
with APC deficiency in the context of intestinal disease, we
acknowledge that many open questions remain regarding the
mechanistic relationship between uncontrolled WNT signalling
and activation of these specific molecules. Nonetheless, the data
presented go some way to demonstrate that while drugs designed
to suppress small GTPase signalling through targeting of specific
GEFs may have significant therapeutic impact in early disease,
they may ultimately fail in more complex late stage disease, due
not only to functional redundancy but also due to inherent
plasticity within upstream regulatory networks.
Materials and methods
Mouse experiments. All experiments were performed under the UK Home Office
Regulations (Owen Sansom PPL 70-8646) in adherence with the ARRIVE guidelines
and approved by the University of Glasgow Animal Welfare Ethical Review Board.
Vil-CreERT2 and Lgr5-EGFP-IRES-creERT2 mice of both sexes and of a mixed
genetic background were used throughout. Mice were housed in conventional
caging with environmental enrichment on a 12-h light–dark cycle with access to
food and water ad libitum. Mice were induced between the age of 6 and 12 weeks,
once they had reached a minimum weight of 20 g and were assessed for symptoms
of ill health at least 3 times per week. The alleles used for this study were as follows;
Vil-CreERT260, Lgr5-EGFP-IRES-creERT261, Apc580S62, KrasLSL-G12D57, Rac1fl63,
Vav2−/−64, Vav3−/−65, Tiam1−/−34, LifeAct-GFP42 and Raichu-Rac154. Recombi-
nation by Vil-CreERT2 was induced by a single intraperitoneal (IP) injection of
tamoxifen (80mgkg−1) per day for 2 days in the context of Apcfl/fl animals, and
1 day in the case of Apcfl/fl; KrasLSL-G12D/+ animals. Tumourigenicity studies were
carried out using Lgr5-EGFP-IRES-creERT2, and mice were induced by one IP
injection of 120mg/kg tamoxifen followed by 3 daily doses of 80mg/kg. Mice were
aged until they reached endpoint (pale feet and weight loss). AOM-DSS colitis-
associated CRC was generated through one IP injection of 12mg/kg AOM (Sigma
Aldrich), 5 days after which 2.5% DSS (MP Biomedicals, MQ 36-50kDA) was given
orally in the drinking water for 5 days, followed by 16 days of normal water. This
DSS cycle was carried out a total of three times after which the mice were killed and
samples taken for histological analysis. The liver work was carried out following
Cre-mediated recombination using AAV8.TBG.Pi.Cre.rBG53. Viral induction was
administered through tail vain induction at a concentration of 2.5 × 1011 copies/ml.
Mice were killed 8 days post induction and livers and serum were taken for analysis.
Immunohistochemistry. All immunohistochemistry was carried out using samples
fixed in 10% neutral-buffered formalin for 12–18 h at 4 °C prior to paraffin
embedding. Antigen retrieval was performed using citrate pH 6 heat mediated
antigen retrieval. Primary antibodies and concentrations were used as follows;
VAV1 (1:50; Cell Signalling #2502), RAC1 (phospho S71) (1:500; Abcam
Ab203884); CDC42 (1:200; Abcam Ab155940);66 Active RAC1 (1:500, NewEast
Biosciences; cat# 26903)67, Cleaved caspase-3 (1:500; Cell Signalling; cat# 9661)68,
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E-Cadherin (clone 24E10, 1:200; Cell Signalling cat#3195)69, SOX9 (1:500; Milli-
pore; cat# AB5535), β-catenin (1:50; BD Biosciences; cat#610154)70, CD44 (1:100;
BD Biosciences; cat# 550538)71, MDA (1:100; Abcam Ab6463);13 VAV2 (1:200;
Abcam Ab79182); VAV3 (1:200; Abcam; Ab203315); CTGF (1:200; Abcam;
Ab6992)48. Secondary HRP-tagged secondaries were used as follows; Dako Envi-
sion+ system HRP goat anti-mouse (neat; Dako K4001), Dako Envision+ system
HRP goat anti-rabbit (neat; Dako K4003). Secondary fluorescent antibodies were
used as follows; Alexafluor-488 (1:200; ThermoFisher; cat # A11034) and Alexa-
Fluor 594 (1:200; ThermoFisher; cat #A11032). Proliferation was determined by
quantifying BrdU incorporation (1:500; BD Biosciences Cat # 347580).
RNAscope probes; Vav2 (ACD 437428), Lgr5 (ACD 312178), Olfm4 (ACD 311838),
c-Myc (ACD 413458) and Axin2 (ACD 400338) were 2.5 LS probes obtained from
ACD, and were stained using the 2.5LS reagent kit-brown (ACD 322100) on the Leica
Bond Rx autostainer. BaseScope Probe; Rac1 (ACD 710331) was stained using the
BaseScope detection reagents red kit (322910) following the manufacturers’ instructions.
Tumour burden analysis. Using Lgr5-EGFP-IRES-creERT2 to drive APC loss
results in a lawn of microscopic tumours as opposed to macroscopic tumours. As
such, we used Halo v 3.1.1076.363 (Indica labs) to microscopically determine the
total area of tissue and the percentage of this that is composed of lesions and
tumours.
Consensus molecular sequencing analysis. CRC patient expression data (Illu-
mina HiSeq, N= 326) was obtained from the TCGA project using the FIREHOSE
repository (https://gdac.broadinstitute.org/). CMS labels for the patients were
obtained from Guinney et al.47 P values were calculated using the limma R
package72 and Benjamini–Hochberg multiple testing correction was applied72,73.
Assessment of RAC1 activity through immunoprecipitation of RAC1-GTP.
RAC1 activity was determined on snap frozen small intestinal tissue and performed
using the Cytoskeleton Rac1-activation assay kit (Cytoskeleton; #BK035) according
to the manufacturer’s instructions. Briefly, tissues were lysed with lysis buffer
supplemented with protease inhibitors. Around 800 μg of lysates was precleared
and PAK-PBD beads were added to pull-down active Rac1. Positive (GTPγS) and
negative (GDP) bound control samples were prepared according to standard
protocol (Cytoskeleton). Following immunoprecipitation at 4 °C for 1 h, beads
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were washed 3x in washing buffer, and precipitated proteins detected by poly-
acrylamide gel electrophoresis and subsequent western blotting. Protein bound
membranes were incubated overnight at 4 °C together with primary anti-Rac1
monoclonal antibody (Cytoskeletion; #ARC03; 1:500) in block solution (TBS
containing 5% BSA, and 0.02% Triton X-100). After washing the membranes
thoroughly in TBS-T, they were incubated 1 h at room temperature with secondary
goat mouse antibody (Agilent #P044701-2, 1:2000) in blocking solution. For
assessment of total RAC1 in whole cell lysates (20 μg protein/sample), mouse anti-
RAC1 antibody (Cytoskeletion; #ARC03; 1:500) was used.
RNA isolation. RNA was isolated from mouse intestinal tissue collected 5 cm distal
from the stomach. RNA isolation from whole intestinal tissue required dissociation
using a Precellys 24 homogeniser (Bertin), and RNA was isolated using a Qiagen
RNeasy Mini Kit (Qiagen, Crawley, West Sussex, UK), according to the manu-
facturer’s instructions. RNA isolation from organoids required isolation of orga-
noids (detailed below) from intestinal tissue. Cells were cultured for 3 days and
then snap frozen. RNA was then extracted using a Qiagen RNeasy Mini Kit. In
both cases, DNAse treatment was performed using Qiagen DNAse (cat #72954).
RNA-sequencing library generation and sequencing. The quality and quantity
of purified RNA was determined using an Agilent 2200 Tapestation with RNA
screentape (Agilent, ThermoFisher Scientific) (RIN of at least 8 was required).
RNA-seq libraries were generated as described in TruSeq RNA Sample Preparation
Guide (illumina, part no. RS-122-2001) using Illumina TruSeq RNA LT sample
preparation kit. PolyA selection step was performed on 1 µg of total RNA; followed
by an 8 min heat fragmentation step aimed at producing libraries with an insert
size between 120 bp and 200 bp. First strand cDNA was synthesised from the
enriched and fragmented RNA using SuperScript III Reverse Transcriptase (Invi-
trogen, 18080-044) and random primers. Second strand synthesis was performed to
produce ds cDNA. Following end repair; 3′ adenylation and ligation of adaptors to
the dsDNA was performed; libraries were subjected to 13 cycles of PCR. RNA-seq
libraries were quantified using Qubit v2.0 HS DNA assay (Invitrogen, Q32854) and
sized and qualified using an Agilent 2200 TapeStation with Agilent D1000
ScreenTape (Agilent, 5067-5582). Libraries were normalised to 4 nM and pooled
before clustering and sequencing (36 bp paired-end) on a NextSeq500 sequencer
(illumina)74.
The libraries were run on an Illumina Next Seq instrument using the High
Output 75 cycles kit (2 × 36 cycles, paired end reads, single index). Fastq files are
deposited at Gene Expression Omnibus (NCBI), study accession numbers;
GSE112226 and GSE152388.
RNA-sequencing analysis. Raw sequence quality was assessed using the FastQC
algorithm version 0.11.8, then sequences were trimmed to remove adaptor
sequences and low-quality base calls, defined as those with a Phred score of <20,
using the Trim Galore tool version 0.6.4. Trimmed sequences were aligned to
mouse genome build GRCm38.98 using HISAT2 version 2.1.0, then raw counts per
gene were determined using FeatureCounts version 1.6.4. Differential expression
analysis was performed using the R package DESeq2 version 1.22.2, and principal
component analysis was performed using R base functions.
Biochemical analysis of Serum. Blood was obtained post-mortem by cardiac
puncture at 8 days post induction with AAV8.TBG.Pi.Cre.rBG viral injection.
Blood was collected into a microcentrifuge tube and allowed to clot at room
temperature. The samples were then centrifuged at 10,000 × g for 10 min at 4 °C
and the serum collected. This serum was analysed on the Siemens Dimension
Expand clinical chemistry system using the IFCC parameters.
Crypt isolation. Organoids were isolated from murine intestines 4 days post
induction. The proximal 10 cm of the small intestine was opened longitudinally
and washed with PBS. This proximal intestine was scraped using a coverslip to
remove and discard the villi and subsequently cut into small (5 mm) pieces. These
pieces were washed with ice-cold PBS and subsequently incubated in 2 mM EDTA
in PBS and incubated at 4 °C for 30 min. The tissue was washed with ice-cold PBS
with washes 2–4 being collected (crypt enriched fractions). These fractions were
diluted with Advanced DMEM/F12 and centrifuged (1200 rpm for 5 min). The
pellets were resuspended in Advanced DMEM/F12 and passed through a 70-µm
cell strainer75. Roughly 100 crypts were plated in 30 μl Matrigel (BD Bioscience) in
a 24-well plate with Advanced DMEM/F12 supplemented with 50 ng/µl EGF
(Peprotech) and 100 ng/µl Noggin (Peprotech). For clonogenicity assays, estab-
lished cultures were dissociated to single cells by resuspending a cell pellet in 1 ml
of TripLE (Gibco by LifeTechnologies), 100 µl DNase buffer and 10 µl DNase
enzyme (Qiagen), incubated for 1 h at 37 °C (or until a single-cell suspension was
achieved). The cells were passed through a 40 µl cell strainer and counted. Cells
were plated at 10,000 cells/well in a 24-well plate and grown for 5 days. After
5 days, established organoids were counted and numbers normalised to Vil-
CreERT2 Apcfl/fl cultures, where three biological replicates and at least three tech-
nical replicates were used per genotype.
Scanning electron microscopy. Tissue samples were fixed in Karnovskys fixative
for 24 h at 4 °C then rinsed and stored in 0.1 M cacodylate buffer. The specimens
were then dehydrated by immersion in a graded series of acetones (30%, 50%, 70%,
80%, 90%, 95% and 100%) each for 5 min. Critical point drying was carried out
using an EMS 850 Critical Point Dryer (EMS, Hatfield, UK). Once dry, the tissues
were mounted on aluminium stubs using quick drying silver conductive adhesive
paint then coated with gold/palladium using an Emscope SC500A sputter coater.
The specimens were viewed using a Hitachi S-570 Scanning electron microscope at
an operating voltage of 15 kV and working distance of 12. Images were captured
using a high resolution image capture system linked to the SEM (Raith GmbH,
Germany).
In-vivo imaging. Intestinal tissue sections were taken from the Vil-CreERT2Apcfl/fl,
LifeAct-GFP mice lacking VAV2, VAV3 and TIAM1 or appropriate controls.
Tissue was placed either crypt up or villus up on a 20-mm glass-bottom microwell
dish (MatTek) with a drop of PBS on top to prevent the tissue from drying out.
Fig. 6 Oncogenic mutation of KRAS drives resistance to RAC-GEF depletion. a Quantification of BrdU positive cells. N= 5, 5 and 10 biologically
independent animals for Vil-CreERT2 Apcfl/fl KRasG12D (APC KRAS), Vil-CreERT2 Apcfl/fl, KRasG12D, Rac1fl/fl (APC KRAS Rac1fl/fl) and Vil-CreERT2 Apcfl/fl,
KRasG12D, Vav2−/−, and Vav3−/− Tiam1−/− (APC KRAS V2V3T) respectively. APC KRAS vs APC KRAS Rac1fl/fl p= 0.0461 APC KRAS vs APC KRAS V2V3
p= 0.9363 as determined by a two-tailed Kruskal–Wallis statistical analysis with Dunn’s mutltiple comparisons test (under the control of Vil-CreERT2).
Data are presented as mean values ±SD. b Representative images for BrdU incorporation of Vil-CreERT2 Apcfl/fl KRasG12D (APC KRAS), Vil-CreERT2 Apcfl/fl,
KRasG12D, Rac1fl/fl (APC KRas Rac1fl/fl) and Vil-CreERT2 Apcfl/fl, KRasG12D, Vav2−/− and Vav3−/− Tiam1−/− (APC KRAS V2V3T). Scale bar represents 100
µm. c Representative images of RNAscope for Lgr5 and Olfn4 and IHC for CD44 and SOX9 Vil-CreERT2 Apcfl/fl KRasG12D (APC KRAS), Vil-CreERT2 Apcfl/fl,
KRasG12D, Rac1fl/fl (APC KRAS Rac1fl/fl) and Vil-CreERT2 Apcfl/fl, KRasG12D, Vav2−/− and Vav3−/− Tiam1−/− (APC KRAS V2V3T). Scale bar represents 100
µm. d Quantification of Lgr5 RNAscope. Vil-CreERT2 Apcfl/fl KRasG12D (APC KRAS vs Vil-CreERT2 Apcfl/fl, KRasG12D, Rac1fl/fl (APC KRAS Rac1fl/fl) p= 0.1105
APC KRAS vs Vil-CreERT2 Apcfl/fl, KRasG12D, Vav2−/−, Vav3−/− Tiam1−/− (APC KRAS V2V3T). n= 6, 5 and 8 biologically independent animals for APC
KRAS, APC KRAS Rac1fl/fl, and APC KRAS V2V3T respectively. p= >0.999 as determined by a two-tailed Kruskal–Wallis statistical analysis with Dunn’s
mutltiple comparisons test (under the control of Vil-CreERT2). Data are presented as mean values ±SD. e Quantification of Olfm4 RNAscope. Vil-CreERT2
Apcfl/fl KRasG12D (APC KRAS) vs Vil-CreERT2 Apcfl/fl, KRasG12D, Rac1fl/fl (APC KRAS Rac1fl/fl) p= 0.356 APC KRAS vs Vil-CreERT2 Apcfl/fl, KRasG12D, Vav2−/−,
Vav3−/− Tiam1−/− (APC KRAS V2V3T). n= 6, 4 and 9 biologically independent animals for APC KRAS, APC KRAS Rac1fl/fl and APC KRAS V2V3T
respectively. p= 0.9381 as determined by a two-tailed Kruskal–Wallis statistical analysis with Dunn’s mutltiple comparisons test (under the control of Vil-
CreERT2). Data are presented as mean values ±SD. f Quantification of CD44 IHC. Vil-CreERT2 Apcfl/fl KRasG12D (APC KRAS) vs Vil-CreERT2 Apcfl/fl, KRasG12D,
Rac1fl/fl (APC KRAS Rac1fl/fl) p= 0.2061 APC KRAS vs Vil-CreERT2 Apcfl/fl, KRasG12D, Vav2−/−, Vav3−/− Tiam1−/− (APC KRAS V2V3T). n= 7, 4 and 8
biologically independent animals for APC KRAS, APC KRAS Rac1fl/fl and APC KRAS V2V3T respectively. p= >0.999 as determined by a two-tailed
Kruskal–Wallis statistical analysis with Dunn’s mutltiple comparisons test (under the control of Vil-CreERT2). Data are presented as mean values ±SD.
g Quantification of SOX9 IHC. Vil-CreERT2 Apcfl/fl KRasG12D (APC KRAS) vs Vil-CreERT2 Apcfl/fl, KRasG12D, Rac1fl/fl (APC KRAS Rac1fl/fl) p= >0.999 APC
KRAS vs Vil-CreERT2 Apcfl/fl, KRasG12D, Vav2−/−, Vav3−/− Tiam1−/− (APC KRAS V2V3T). n= 7, 5 and 9 biologically independent animals for APC KRAS,
APC KRAS Rac1fl/fl and APC KRAS V2V3T respectively p= 0.4088 as determined by a two-tailed Kruskal–Wallis statistical analysis with Dunn’s mutltiple
comparisons test (under the control of Vil-CreERT2). Data are presented as mean values ±SD.
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Imaging was carried out on LaVision Biotech TRIMscope multiphoton microscope,
obtaining Z-stacks of 400 μm at 0.4 μm intervals. A Coherent Chameleon Ultra II
Ti:Sapphire laser was used at 890 nm to generate fluorescence and second har-
monic signal simultaneously. A sequence of dichroic and band-pass filters were
employed to spectrally separate the emission. A 500 LP dichroic (Chroma 500dclp)
reflects the SHG signal through a Semrock 435/40 nm band-pass filter and trans-
mits through to a Semrock 525/50 nm band-pass filter for the GFP emission. An
exponential power increase was applied automatically with increasing focusing
depth to counteract the tissue induced scattering of the light. At least three mice
were imaged for each genotype.
FLIM-FRET. Organoids derived from the intestinal epithelium of Vil-CreERT2
Apcfl/fl and Vil-CreERT2 Apcfl/fl Vav2−/− Vav3−/− Tiam1−/− mice were isolated as
described above75. Three days post isolation, the organoids were imaged on a
LaVision Biotec TRIMscope multiphoton microscope using the same setup as used
for LifeAct-GFP imaging, however, the PMT used to image the GFP emission was
replaced with a Hamamatsu hybrid-PMT operating in a photon counting mode to
act as TCSPC FLIM detector. Care was taken to use laser power low enough as to
not cause photon pile-up, but sufficient to generate signal for accurate curve fitting.
Analysis was performed using the built-in non-linear curve fitting routine in the
Imspector package from LaVision Biotec (version 7_0_153), and briefly, a tail
fitting method was used to exclude the excitation peak and fit a single exponential
decay to the fluorescence decay stored at each pixel separately. The decay lifetime
was then recorded on a cell by cell basis. At least five cell contacts per organoid
were analysed, with at least four organoids per cell line imaged, and separate cell
lines generated from three mice of each genotype.
Statistics and reproducibility. All statistical analyses were carried out using
GraphPad Prism V7.02. The Statistical tests used are indicated where appropriate
in figure legends. Power analyses were calculated using G* power v3.1.9.4. For
p values where >0.999 is stated, this is considered as an exact value by Prism. All
statistical tests have been mentioned in their respective legends, where they can be
sided this has been stated.
For all in vivo analysis each data point represents a biologically unique animal.
The clonogenecity and FLIM-FRET experiments were comprised of three
biologically distinct replicates and at least three technical replicates.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
RNAseq data that support the findings in this manuscript have been deposited at Gene
Expression Omnibus (NCMI) with the study accession codes; GSE112226 and
GSE152388. Data for the consensus molecular sequencing analysis, CRC patient
expression data was obtained from the TCGA project using the FIREHOSE repository
(https://gdac.broadinstitute.org/). Source data are provided with this paper.
Received: 19 June 2017; Accepted: 17 November 2020;
References
1. Aznar, S. & Lacal, J. C. Rho signals to cell growth and apoptosis. Cancer Lett.
165, 1–10 (2001).
2. Hanna, S. & El-Sibai, M. Signaling networks of Rho GTPases in cell motility.
Cell Signal. 25, 1955–61. (2013).
3. Ridley, A. J. et al. The small GTP-binding protein rac regulates growth factor-
induced membrane ruffling. Cell 70, 401–410 (1992).
4. Nobes, C. D. & Hall, A. Rho. Rac and CDC42 GTPases regulate the assembly
of multimolecular focal complexes associated with actin stress fibers,
lamellipodia, and filopodia. Cell 81, 53–62 (1995).
5. Sander, E. E. & Collard, J. C. Rho-like GTPases: their role in epithelial cell-cell
adhesion and invasion. Eur. J. Cancer 35, 1302–1308 (1999).
6. Moore, K. A. et al. Rac1 is required for cell proliferationand G2/M
progression. Biochem. J. 326, 17–20 (1997).
7. Gastonguay, A. et al. The role of Rac1 in the regulation of NF-kappaB activity,
cell proliferation, and cell migration in non-small cell lung carcinoma. Cancer
Biol. Ther. 13, 647–56 (2012).
8. Hart, M. J. et al. Cellular transformation and guanine nucleotide exchange
activity are catalyzed by a commone domain on the dbl oncogene product. J.
Biol. Chem. 269, 62–65 (1993).
9. Matos, P. & Jordan, P. Increased Rac1b expression sustains colorectal tumor
cell survival. Mol. Cancer Res. 6, 1178–84. (2008).
10. Davis, M. J. et al. RAC1P29S is a spontaneously activating cancer-associated
GTPase. Proc. Natl Acad. Sci. USA 110, 912–917 (2013).
11. Wang, T. et al. Gene essentiality profiling reveals gene networks and synthetic
lethal interactions with oncogenic Ras. Cell 168, 890–903 e15 (2017).
12. Powell, S. et al. APC mutations occur earl during colorecatl tumorigenesis.
Nature 359, 235–237 (1992).
13. Cheung, E. C. et al. Opposing effects of TIGAR- and RAC1-derived ROS
on Wnt-driven proliferation in the mouse intestine. Genes Dev. 30, 52–63
(2016).
14. Myant, K. B. et al. ROS production and NF-kappaB activation triggered by
RAC1 facilitate WNT-driven intestinal stem cell proliferation and colorectal
cancer initiation. Cell Stem Cell 12, 761–73 (2013).
15. Sparks, A. B. et al. Mutational analysis of the APC/b-catenin/Tcf pathway in
colorectal cancer. Cancer Res. 58, 1130–1134 (1998).
16. Kinzler, K. W. & Voglestein, B. Lessions from hereditary colorectal cancer.
Cell 87, 159–170 (1996).
17. Sansom, O. J. et al. Loss of Apc in vivo immediately perturbs Wnt signaling,
differentiation, and migration. Genes Dev. 18, 1385–90 (2004).
18. Barker, N. et al. Crypt stem cells as the cells-of-origin of intestinal cancer.
Nature 457, 608–11 (2009).
19. Schmidt, A. & Hall, A. Guanine nucleotide exchange factors for Rho GTPases:
turning on the switch. Genes Dev. 16, 1587–609 (2002).
20. Ihara, K. et al. Crystal structure of human RhoA in a dominantly active form
complexed with a GTP analogue. J. Biol. Chem. 273, 9656–9666 (1998).
21. Dvorsky, R. & Ahmadian, M. R. Always look on the bright site of Rho:
structural implications for a conserved intermolecular interface. EMBO Rep. 5,
1130–1136 (2004).
22. Cherfils, J. & Zeghouf, M. Regulation of small GTPases by GEFs, GAPs, and
GDIs. Physiol. Rev. 93, 269–309 (2013).
23. Cote, J. F. & Vuori, K. GEF what? Dock180 and related proteins help Rac to
polarize cells in new ways. Trends Cell Biol. 17, 383–93 (2007).
24. Lindsay, C. R. et al. P-Rex1 is required for efficient melanoblast migration and
melanoma metastasis. Nat. Commun. 2, 555 (2011).
25. Fernandez-Zapico, M. E. et al. Ectopic expression of VAV1 reveals an
unexpected role in pancreatic cancer tumorigenesis. Cancer Cell 7, 39–49 (2005).
26. Bid, H. K. et al. RAC1: an emerging therapeutic option for targeting cancer
angiogenesis and metastasis. Mol. Cancer Ther. 12, 1925–34 (2013).
27. Sugihara, K. et al. Rac2 is required for the formation of three germ layers
during gastrulation. Oncogene 17, 3427–3433 (1998).
28. Mitin, N. et al. Release of autoinhibition of ASEF by APC leads to CDC42
activation and tumor suppression. Nat. Struct. Mol. Biol. 14, 814–23 (2007).
29. Jiang, H. et al. Peptidomimetic inhibitors of APC-Asef interaction block
colorectal cancer migration. Nat. Chem. Biol. 13, 994–1001 (2017).
30. Malliri, A. et al. The rac activator Tiam1 is a Wnt-responsive gene that
modifies intestinal tumor development. J. Biol. Chem. 281, 543–548 (2006).
31. Patel, V. et al. Persistent activation of Rac1 in squamous carcinomas of the
head and neck: evidence for an EGFR/Vav2 signaling axis involved in cell
invasion. Carcinogenesis 28, 1145–1152 (2007).
32. Salhia, B. et al. The guanine nucleotide exchange factors trio, Ect2, and Vav3
mediate the invasive behavior of glioblastoma. Am. J. Pathol. 173, 1828–38
(2008).
33. Bustelo, X. R. Vav family exchange factors: an integrated regulatory and
functional view. Small GTPases 5, 9 (2014).
34. Malliri, A. et al. Mice deficient in the Rac activator Tiam1 are resistant to Ras-
induced skin tumours. Nature 417, 867–871 (2002).
35. Wong, C. E. et al. Inflammation and Hras signaling control epithelial-
mesenchymal transition during skin tumor progression. Genes Dev. 27,
670–82. (2013).
36. Moser, A. R. et al. ApcMin: a mouse model for intestina and mammary
tumorigenesis. Eur. J. Cell Biol. 7/8, 1061–1064 (1995).
37. Kawasaki, Y. et al. The adenomatous polyposis coli-associated exchange
factors Asef and Asef2 are required for adenoma formation in Apc(Min/+)
mice. EMBO Rep. 10, 1355–62. (2009).
38. Groden, J. et al. Identification and characterisation of the familial
Adenomatous Polyposis Coli gene. Cell 66, 589–600 (1991).
39. Kinzler, K. W. et al. Identification of FAP locus genes from chromoshome
5q21. Science 253, 661–665 (1991).
40. Fearon, E. R. & Vogelstein, B. A genetic model for colorectal tumorigenesis.
Cell 61, 759–767 (1990).
41. Cancer Genome Atlas Network. Comprehensive molecular characterization of
human colon and rectal cancer. Nature 487, 330–337 (2012).
42. Schachtner, H. et al. Tissue inducible Lifeact expression allows visualization of
actin dynamics in vivo and ex vivo. Eur. J. Cell Biol. 91, 923–929 (2012).
43. Riedl, J. et al. Lifeact: a versatile marker to visualize F-actin. Nat. Methods 5,
605–607 (2008).
44. Maldonado, M. D. M. et al. Targeting Rac and Cdc42 GEFs in metastatic
cancer. Front. Cell Dev. Biol. 8, 201 (2020).
45. Cook, D. R. et al. The ect2 rho Guanine nucleotide exchange factor is essential
for early mouse development and normal cell cytokinesis and migration.
Genes Cancer 2, 932–42. (2011).
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-20255-4 ARTICLE
NATURE COMMUNICATIONS |           (2021) 12:56 | https://doi.org/10.1038/s41467-020-20255-4 | www.nature.com/naturecommunications 13
46. Meyers, R. M. et al. Computational correction of copy number effect improves
specificity of CRISPR-Cas9 essentiality screens in cancer cells. Nat. Genet. 49,
1779–1784 (2017).
47. Guinney, J. et al. The consensus molecular subtypes of colorectal cancer. Nat.
Med. 21, 1350–1356 (2015).
48. Diamantopoulou, Z. et al. TIAM1 antagonizes TAZ/YAP both in the
destruction complex in the cytoplasm and in the nucleus to inhibit invasion of
intestinal epithelial cells. Cancer Cell 31, 621–634.e6 (2017).
49. Kimelman, D. & Xu, W. beta-catenin destruction complex: insights and
questions from a structural perspective. Oncogene 25, 7482–91 (2006).
50. Jamieson, C. et al. Rac1 augments Wnt signaling by stimulating beta-catenin-
lymphoid enhancer factor-1 complex assembly independent of beta-catenin
nuclear import. J. Cell Sci. 128, 3933–46 (2015).
51. Colnot, S. et al. Liver-targeted disruption of Apc in mice acitavtes b-catenin
signaling and leads of hepatocellular carcinomas. Proc. Natl Acad. Sci. USA
101, 17216–17221 (2004).
52. Reed, K. R. et al. B-Catenin deficiency, but not Myc deletion, suppresses the
immediate phenotypes of APC loss in the liver. Proc. Natl Acad. Sci. USA 105,
18919–18923 (2008).
53. Raven, A. et al. Cholangiocytes act as facultative liver stem cells during
impaired hepatocyte regeneration. Nature 547, 350–354 (2017).
54. Johnsson, A. E. et al. The Rac-FRET mouse reveals tight spatiotemporal control
of Rac activity in primary cells and tissues. Cell Rep. 6, 1153–1164 (2014).
55. Itoh, R. E. et al. Activation of rac and cdc42 video imaged by fluorescent
resonance energy transfer-based single-molecule probes in the membrane of
living cells. Mol. Cell Biol. 22, 6582–91 (2002).
56. Diebold, B. A. et al. Antagonistic cross-talk between Rac and Cdc42 GTPases
regulates generation of reactive oxygen species. J. Biol. Chem. 279, 28136–42
(2004).
57. Tuveson, D. A. et al. Endogenous oncogenic K-rasG12D stimulates
proliferation and widespread neoplastic and developmental defects. Cancer
Cell 5, 375–387 (2004).
58. Cammareri, P. et al. TGFbeta pathway limits dedifferentiation following WNT
and MAPK pathway activation to suppress intestinal tumourigenesis. Cell
Death Differ. 24, 1681–1693 (2017).
59. Besray Unal, E. et al. Systems level expression correlation of Ras GTPase
regulators. Cell Commun. Signal. 16, 46 (2018).
60. el Marjou, F. et al. Tissue-specific and inducible Cre-mediated recombination
in the gut epithelium. Genesis 39, 186–93 (2004).
61. Barker, N. et al. Identification of stem cells in small intestine and colon by
marker gene Lgr5. Nature 449, 1003–1007 (2007).
62. Shibata, H. et al. Rapid colorectal adenoma formation initiated by conditional
targeting of teh Apc gene. Science 278, 120–123 (1997).
63. Walmsley, M. J. et al. Critical roles for Rac1 and Rac2 GTPases in B cell
development and signaling. Science 302, 459–462 (2003).
64. Doody, G. M. et al. Signal transduction through Vav-2 participates in
humoral immune responses and B cell maturation. Nat. Immunol. 2, 542–547
(2001).
65. Fujikawa, K. et al. Vav1/2/3-null mice define an essential role for Vav family
proteins in lymphocyte development and activation but a differential requirement
in MAPK signaling in T and B cells. J. Exp. Med. 198, 1595–608 (2003).
66. Dubrac, A. et al. Targeting NCK-mediated endothelial cell front-rear polarity
inhibits neovascularization. Circulation 133, 409–21 (2016).
67. Dai, Y. K. et al. A link between the nuclear-localized srGAP3 and the
SWI/SNF chromatin remodeler Brg1. Mol. Cell. Neurosci. 60, 10–25 (2014).
68. Wen, S. et al. Necroptosis is a key mediator of enterocytes loss in intestinal
ischaemia/reperfusion injury. J. Cell. Mol. Med. 21, 432–443 (2017).
69. Lee, Y. S. et al. Crosstalk between CCL7 and CCR3 promotes metastasis of
colon cancer cells via ERK-JNK signaing pathways. Oncotarget 7,
36842–36853 (2016).
70. Eger, A. et al. Epithelial mesencymal transition by c-Fos estrogen receptor
activation involved nuclear translocation of b-catenin and upregulation of
b-catenin/lymphoid enhancer binding factor-1 transcription activity. J. Cell
Biol. 148, 173–187 (2000).
71. Ritschka, B. et al. The senescence-associated secretory phenotype induces
cellular plasticity and tissue regeneration. Genes Dev. 31, 172–183 (2017).
72. Ritchie, M. E. et al. limma powers differential expression analyses for RNA-
sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).
73. Sievers, F. et al. Fast, scalable generation of high-quality protein multiple
sequence alignments using Clustal Omega. Mol. Syst. Biol. 7, 539 (2011).
74. Fisher, S. et al. A scalable, fully automated process for construction of
sequence-ready human exome targeted capture libraries. Genome Biol. 12, R1
(2011).
75. Sato, T. et al. Single Lgr5 stem cells build crypt-villus structures in vitro
without a mesenchymal niche. Nature 459, 262–265 (2009).
Acknowledgements
All authors are supported by Cancer Research UK. K.A.P. and A.D.C. are funded through
a collaboration with Novartis and R.P.F was funded through a fellowship from the Royal
Commission for the Exhibition of 1851. A.K.N. and L.B.Z. are funded through CRUK
Grand Challenge Rosetta (A25045). S.K.F. is funded through the PCUK Future Leaders
Academy (2017FutureLeadersAcademy). K.G. is funded through CRUK Grand Chal-
lenge Specificancer (A29055). L.M.M., M.B., K.I.A., M.D. and O.J.S. are supported
through CRUK (A15673, A15565, A17096, A21139 and A17196 respectively). A.K.J. and
M.T. are supported by BBSRC. M.B. is supported by University of Glasgow. D.M.G. and
O.J.S. were also funded through ERC ColonCan (ERC starting grant 311301). Addi-
tionally, K.A.P., A.D.C., D.M.G., J.J., R.P.F., B.M., W.C., A.H., E.M., L.M.M., C.N., D.S.,
K.I.A., M.D. and O.J.S. are supported by CRUK Beatson core funding (A17196). Thanks
to Glasgow University Veterinary Diagnostic services for blood serum analysis. Thanks
to histology, microscopy and the BSU for enabling this work to be carried out. Thanks to
Victor Tybulewicz for Rac1 flox mice, and Heidi Welch for Raichu-Rac1 report mice. We
thank Heidi Welch for critical review of the manuscript.
Author contributions
O.J.S., K.A.P., A.D.C. and K.M., conceived and designed the project. K.A.P., K.G., J.W.C.,
R.P.F., S.K.F., A.K.N., L.B.Z., D.F.V., D.M.G., J.J., B.M., W.C., A.H., E.B.U., C.K., E.M.,
C.N., M.B., S.R.V.H., J.P.M., K.I.A., S.M.B., V.M.S., M.D., L.S. and K.M. contributed to
acquisition of data and analysed the data. L.M.M., A.E.J., A.M., M.T. and D.S. con-
tributed to the development of mouse models. K.A.P., A.D.C., K.M. and O.J.S. inter-
preted the data. K.A.P., A.D.C. and O.J.S. wrote the manuscript.
Competing interests
The authors declare no competing interests.
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41467-
020-20255-4.
Correspondence and requests for materials should be addressed to K.M., A.D.C. or O.J.S.
Peer review information Nature Communications thanks Giorgio Scita and the other,
anonymous, reviewer(s) for their contribution to the peer review of this work.
Reprints and permission information is available at http://www.nature.com/reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2021
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-20255-4
14 NATURE COMMUNICATIONS |           (2021) 12:56 | https://doi.org/10.1038/s41467-020-20255-4 | www.nature.com/naturecommunications
